Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.

Fiche publication

Date publication

juillet 2019


Journal of cancer research and clinical oncology


Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Pr BORG Christophe, Pr GHIRINGHELLI François, Dr JOUVE Jean-Louis, Dr VINCENT Julie, Pr LOFFROY Romaric, Dr BENGRINE-LEFEVRE Leila

Tous les auteurs :
Ghiringhelli F, Vincent J, Bengrine L, Borg C, Jouve JL, Loffroy R, Guiu B, Blanc J, Bertaut A


Hepatic arterial infusion (HAI) of chemotherapy could be used in patients with liver-only metastatic colorectal cancer (mCRC) to fight against chemoresistance. We previously reported the efficacy of raltitrexed plus oxaliplatin (HAI) in a retrospective series. We performed a randomized two-stage phase-II study to evaluate the efficacy of HAI of the combination of raltitrexed and oxaliplatin in refractory mCRC with only liver metastases in comparison with standard of care.

Mots clés

Colorectal cancer, Hepatic arterial infusion, Liver metastasis, Oxaliplatin, Raltitrexed


J. Cancer Res. Clin. Oncol.. 2019 Jul 4;: